Reports and Briefs on Pharmaceuticals in Middle East and Africa

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Report
Report

Biosimilars: Pipeline Trends

The report provides an overview of biosimilar and copy-biologic product landscape, split by marketed and pipeline products, target therapy areas and indications, geography, and drug developers.

Published By Datamonitor
09 Dec 2011 $2800
Buy
Report
Report

In Vitro Diagnostics M&A and Deal Trends

This report provides an analysis of strategies and trends employed by companies operating in the in vitro diagnostics (IVDs) market in order to drive revenue growth.

Published By Datamonitor
17 Jul 2012 $2800
Buy
Report
Report

Lifecycle Management Strategies: Reformulations – Success hinges on delivering significant improvement in disease outcome

This report analyzes reformulation as a brand lifecycle management strategy and includes an overview of the strategy with key success drivers and resistors and successful and unsuccessful case studies of reformulated brands.

Published By Datamonitor
24 Jul 2012 $1520
Buy
Report
Report

Lifecycle Management Strategies: Pharma-Payer Deals - Creative agreements are used at different stages of the brand lifecycle to maximize sales

This report analyzes pharma-payer deals as a brand lifecycle management strategy and includes an overview of the strategy with key success drivers and resistors and successful and unsuccessful case studies of such deals.

Published By Datamonitor
16 Aug 2012 $1520
Buy
Report
Report

Partnership Models and Emerging Destinations for R&D Outsourcing

This report reviews the different types of relationship models between contract research organizations (CROs) and sponsors, and forecasts the leading next-wave clinical trial destinations.

Published By Datamonitor
23 Aug 2012 $2800
Buy
Report
Report

Strategies for Comparative Efficacy Trials

Comparative efficacy data are not necessarily required for approval but are increasingly demanded by payers. Meeting the expectations of all stakeholders can be challenging, making comparator selection and trial design complex decisions.

Published By Datamonitor
23 Aug 2012 $2800
Buy
Report
Report

Drug Discovery for Rare Diseases

Favorable legislation and recent commercial successes have stimulated growing interest in the discovery of novel orphan drugs. However, there are many strategic considerations that are peculiar to the R&D process for diseases of low prevalence.

Published By Datamonitor
31 Aug 2012 $2800
Buy
Report
Report

Delivery Across the Blood-Brain Barrier

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $2800
Buy
Report
Report

Central Nervous System Drug Delivery Specialists

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel CNS treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $2800
Buy
Report
Report

Strategies and Technologies for Target Validation

High Phase II attrition is hampering the pharma industry’s ability to reach sustainable rates of innovation. More rigorous validation of new biological targets prior to clinical development is essential for increasing R&D efficiency.

Published By Datamonitor
28 Sep 2012 $2800
Buy

« | 1 | 2 | » »|

No help is available.